| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Suvratoxumab
CAS:1629620-18-3
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Suvratoxumab
CAS:1629620-18-3
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Suvratoxumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Suvratoxumab (DXX00102)
CAS:1629620-18-3
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Suvratoxumab Basic information |
| Product Name: | Suvratoxumab | | Synonyms: | Suvratoxumab;Research Grade Suvratoxumab (DXX00102);Research Grade Suvratoxumab | | CAS: | 1629620-18-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Suvratoxumab Structure]() |
| | Suvratoxumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Suvratoxumab Usage And Synthesis |
| Uses | Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394)[1][2][3]. | | in vivo | Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) increases survival rates in an immunocompromised murine pneumonia model[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis reduces pulmonary damage and increases macrophage phagocytosis in mice[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis improves the effectiveness of antibiotic (vancomycin or linezolid) treatment in mice[1]. | Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 5, 15, 45 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU. |
| Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Prophylaxis protected the lungs of S. aureus-infected immunocompromised mice from α toxin-mediated damage. |
| | References | [1] Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. DOI:10.1128/AAC.00510-15
[2] Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16. DOI:10.1128/AAC.01020-16
[3] Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. DOI:10.1074/jbc.M114.601328 |
| | Suvratoxumab Preparation Products And Raw materials |
|